Development is Risky, Costly, & Stagnant
Stifles Innovation
in the healthcare industry
Unnecessary Risks and Losses
in research and development
Impedes
the creation for patient treatment options
Smart Science Platform
The PHDC Smart Science Platform enables real-time, on-demand test development which saves time and cost in research and development. PHDC is a fully integrated data-to-diagnostic production platform that’s taking the risk out of clinical R&D projects.
- Distribute returns to shareholders
- Validation Both analytical and clinical
- Leverage research and development from others
- IP Protection Patent trade secrets
- Verification CLIA and LDT validation
- Commercialize Create market LDT/FDA
From Preliminary Launch to FDA Approval
Smart Diabetes
Diabetes Prevent is more than a pioneering risk evaluation genetic test. It aims to help you control and prevent type 2 diabetes.
Smart Path
Rapid Slide-Free Pathology Instrument with Potential to Fundamentally Improve Diagnostic Microscopy.
Smart VascularDX
Endothelial Damage in Arteries & Guide Therapy. 2.5x More Sensitive than hsCRP for Inflammation.
Smart KidneyDX
A biomarker-based algorithm that confirms the diagnosis, grades the tumor, and predicts risk of metastases
Smart LungDX
Molecular Diagnostic with a 93% Sensitivity & 57% Specificity. PHDC will gain clinical validation for this technology with less than $2M in R&D spending, in just 12 months.
Smart CellDX
Cardiovascular Disease (CVD) tests currently lack specificity with only cholesterol and lipid panel results
Heart Attack Prevention with PULS
What Patients Say About Us
There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which don't look even believable.
There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which don't look even believable.
There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which don't look even believable.
There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which don't look even believable.
News & Media
SmartHealth Dx Featured in Cover Story of Med Tech Outlook Magazine’s Pathology Special Edition
IRVINE, Calif., June 13, 2023 /PRNewswire/ — Smart Health Diagnostics Company (“SHDx” or “the Company”), a developer of precision diagnostic tests that address unmet clinical needs in pathology and vascular inflammation for advancing today’s standards of care, announced that CEO and Chairman Mitch Levine is featured in the June 8, 2023 edition of Med Tech […]
Specialty Diagnostics Technology and Solutions Provider Unveils New Brand Identity as SmartHealth Diagnostics
SmartHealth name unifies multi-function operating platform with smart science diagnostics product suite under common brand
SmartHealth Diagnostics Appoints Accomplished Corporate and Finance Leader Mitch Levine as President, Chief Financial Officer, and Director
Highly regarded diagnostics industry executive and capital markets expert to guide planned growth and value creation for evolutionary data-to-diagnostics platform company
Diagnostic Tests to Improve Patient Care
Company announces its business strategy including test development, commercialization, intellectual property, and reimbursement initiatives
Predictive Health Diagnostics Company Welcomes Susie Lu as President of Laboratory Services for All Company Businesses
Susie Lu as President of Laboratory Services for all Predictive Health Diagnostics Company businesses.
Predictive Health Diagnostics Company Appoints 30-Year Diagnostic Imaging Executive Larry Dentice as Chief Commercial Officer and Director
Larry Dentice as Chief Commercial Officer. Mr. Dentice has also stepped into a board role following the departure of longtime board member Munira Mubarak.
Predictive Health Diagnostics Company’s Morningstar Laboratories Receives Clinical Laboratory Permit from Pennsylvania Department of Health
Morningstar to bring much needed laboratory service resources, including COVID-19 antibody testing, to urban and rural communities statewide
Predictive Health Diagnostics Company’s PULS Cardiac Test Plays Key Role in Detecting Vascular Inflammation Common After Receiving COVID-19 Vaccines
PULS Test vascular inflammation biomarkers and scores reveal risk of developing acute coronary syndrome (ACS) which can be increased in mRNA COVID-19 vaccinated patients
Predictive Health Diagnostics Company Expands Smart Science Diagnostics Platform with Acquisition of MUSE Microscopy Inc.
AI-derived imaging platform expands Company’s test development expertise to create next generation diagnostics for pathology
Predictive Health Diagnostics Company Announces Rollout of Proprietary LIS Cloud-Based Laboratory Information System Software
LIS system enables scalable functionality and big data analysis capabilities
Predictive Health Diagnostics Company’s Morningstar Laboratories Reports Expanding In-Network Provider Participation, Achieves Accreditation from College of American Pathologists (CAP)
Expanding in-network status reflects strong demand and utilization of the PULS Cardiac Testâ„¢ and DIABETESpredictâ„¢ in healthcare settings nationwide
Predictive Health Diagnostics Company Announces Partnership with Madison Core Laboratories for PULS Cardiac Testâ„¢ Distribution to 30+ Healthcare Facilities
Distribution targeted to high at-risk co-morbid patient populations